News
People lost more weight on Zepbound
Digest more
Despite its expensive valuation and declining estimates, we suggest investors hold LLY stock as the company boasts solid ...
People taking Zepbound, Eli Lilly’s obesity drug, lost almost 50% more weight than individuals using Novo Nordisk’s ...
Eli Lilly on Thursday posted better-than-expected quarterly results, but CVS Health's decision to drop the company's obesity ...
Some of the bankrupt company’s closest rivals, newer telehealth firms, face a new challenge of their own as federal ...
Eli Lilly launched a couple of new successful drugs, Mounjaro and Zepbound, that have boosted ... In 2021, Pfizer's COVID-19 vaccine success had many wondering how to invest in Pfizer.
Eli Lilly’s expanding US production and advancing pipeline offset near-term headwinds and support bullish conviction. Read ...
Looking for undervalued stocks? Check out three top undervalued stocks to buy now in May, 2025 to boost your portfolio.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback